Review
Copyright ©The Author(s) 2015.
World J Hepatol. Aug 8, 2015; 7(16): 1987-2008
Published online Aug 8, 2015. doi: 10.4254/wjh.v7.i16.1987
Table 1 Comparison between extracellular and hepatocyte-specific agents (Multihance® and Eovist®)
Extracellular contrast agentsHepatocyte-specific agents
Multihance®Eovist®
AdvantagesRobust arterial and portal venous phase imagingRobust arterial and portal venous phase imagingHepatobiliary imaging
Price and availabilityHepatobiliary imagingShort delay for hepatobiliary phase (20 min)
Smaller dose administrationSmaller dose administration
Safer for renal impaired patientsSafer for renal impaired patients
Price
DisadvantagesNo hepatobiliary phaseAvailability (not available in all countries)Less robust arterial and portal venous phase imaging
NSF cases reported with less stable agentsLonger delay for hepatobiliary phase (90-180 min)Pitfalls for inexperienced readers
Price